Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PTK7 + CPT113
- Development stage
- Preclinical
- Lead developer
- Aadi Bioscience
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
PTK7 + CPT113 is an investigational antibody-drug conjugate combination targeting Protein tyrosine kinase 7 (PTK7) using the CPT113 linker-payload platform delivering a topoisomerase I inhibitor payload; it is being advanced for high PTK7-expressing solid tumors such as non-small cell lung cancer and ovarian cancer. According to ADC Review and company disclosures, the CPT113 platform features a highly stable cleavable linker designed to release a topoisomerase I inhibitor payload, positioning PTK7-CPT113 as part of a next-generation ADC portfolio in-licensed by Aadi Bioscience from Hangzhou DAC for development in PTK7-high cancers.[7][1][10] PTK7 is a catalytically inactive receptor in the non-canonical Wnt pathway implicated in tumor biology and has been clinically explored as an ADC target with earlier auristatin-based PTK7 ADCs (e.g., cofetuzumab pelidotin) showing activity in ovarian cancer, NSCLC, and TNBC, supporting the rationale for a PTK7-directed topoisomerase I ADC approach.[2][4][5]
- Other names
- PTK7-CPT113PTK-7-CPT113PTK 7-CPT113
02
Targets
PTK7 (Protein tyrosine kinase 7)TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on PTK7 + CPT113.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PTK7 + CPT113.